# A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)

> **NCT00262067** · PHASE3 · UNKNOWN · sponsor: **Genentech, Inc.** · enrollment: 1237 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Placebo
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT00262067
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-12
- **Primary completion:** 2008-07
- **Final completion:** 2013-12
- **Target enrollment:** 1237 (ACTUAL)
- **Last updated:** 2013-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00262067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00262067, "A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00262067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*